As part of an ongoing series of studies in its Phase IIIinvestigational new drug (IND) program, Advanced PolymerSystems Inc. (APS) has finished two clinical efficacy studies onits Tretinoin Microsponge Gel technology.
Based on the results of these studies, the company(NASDAQ:APOS) says it will continue preparing to file a newdrug application (NDA) for review by the FDA.
APS of Redwood City, Calif., develops, manufactures and sellspatented Microsponge delivery systems that allow for thecontrolled, programmed release of active ingredients used indermatology, cosmetic and personal care applications.
(c) 1997 American Health Consultants. All rights reserved.